search
Back to results

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Primary Purpose

Liver Cancer

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
hsp90
Sponsored by
Protgen Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Liver Cancer

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Liver cancer patients
  • Healthy volunteers,
  • Benign liver diseases patients

Exclusion Criteria:

  • Patients who Previously accepted radiotherapy

Sites / Locations

  • Zhejiang Medical University Cancer Institute and Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

liver cancer

Arm Description

Detect plasma Hsp90α concentration of liver cancer patients

Outcomes

Primary Outcome Measures

Hsp90α Concentration of plasma
Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit

Secondary Outcome Measures

Full Information

First Posted
December 14, 2014
Last Updated
December 23, 2014
Sponsor
Protgen Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT02324127
Brief Title
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Official Title
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
December 2014
Overall Recruitment Status
Unknown status
Study Start Date
October 2012 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
December 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Protgen Ltd

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.
Detailed Description
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases, validate accuracy, specificity and sensitivity of Hsp90α kit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
liver cancer
Arm Type
Experimental
Arm Description
Detect plasma Hsp90α concentration of liver cancer patients
Intervention Type
Device
Intervention Name(s)
hsp90
Other Intervention Name(s)
biomarker
Intervention Description
Detect plasma Hsp90α concentration of lung cancer patients
Primary Outcome Measure Information:
Title
Hsp90α Concentration of plasma
Description
Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit
Time Frame
4 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Liver cancer patients Healthy volunteers, Benign liver diseases patients Exclusion Criteria: Patients who Previously accepted radiotherapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shusen Zhen, MD
Organizational Affiliation
The first hospital of Zhejiang province
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zhejiang Medical University Cancer Institute and Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China

12. IPD Sharing Statement

Learn more about this trial

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

We'll reach out to this number within 24 hrs